Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1

Conditions

Leukemia, Myeloid, Acute 35Advanced Solid Tumors 20Carcinoma, Non-Small-Cell Lung 14Myelodysplastic Syndromes 13Breast Neoplasms 13Advanced Solid Tumor 13Recurrence 10Ovarian Neoplasms 8Neoplasms 8Multiple Myeloma 8Leukemia, Myelomonocytic, Chronic 8Triple Negative Breast Neoplasms 7Solid Tumor 6Myeloproliferative Disorders 6Small Cell Lung Carcinoma 5Prostatic Neoplasms 5Neoplasm Metastasis 5Lung Neoplasms 5Carcinoma, Hepatocellular 5Advanced Solid Tumour 5Sarcoma 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Melanoma 4Lymphoma, Large B-Cell, Diffuse 4Lymphoma, B-Cell 4Fallopian Tube Neoplasms 4Colorectal Neoplasms 4Advanced Malignant Solid Tumor 4Advanced Lung Cancer 4Squamous Cell Carcinoma of Head and Neck 3

Interventions

pembrolizumab 3Nivolumab 3Ifosfamide 3Doxorubicin 3AZD 6244 3selinexor 2pazopanib 2fludarabine phosphate 2Radiotherapy 2Radiation 2Magnetic Resonance Spectroscopy 2thymoglobulin 1tazemetostat 1metarrestin 1fludarabine 1decitabine and cedazuridine drug combination 1Thiotepa 1Tacrolimus 1Stem Cell Transplantation 1Specimen Handling 1Sirolimus 1Proton Therapy 1Mycophenolic Acid 1Mesna 1Melphalan 1Liquid Biopsy 1Ipilimumab 1Injections 1Etoposide 1Cyclosporins 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neurofibrosarcoma × Injections × 1 year × Clear all
NCT06277154 2025-07-24

MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma

HRYZ Biotech Co.

Phase 2 Recruiting
148 enrolled
GynecologicSarcoma

Fibrosarcoma, Hemangiosarcoma, Leiomyosarcoma, Liposarcoma, Sarcoma, Sarcoma, Synovial, Sarcoma, Endometrial Stromal, Neurofibrosarcoma, Histiocytoma, Malignant Fibrous, Desmoplastic Small Round Cell Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡